New research explains how HIV avoids getting ZAPped

November 11, 2019

ANN ARBOR--Humans have evolved dynamic defense mechanisms against the viruses that seek to infect our bodies--proteins that specialize in identifying, capturing and destroying the genetic material that viruses try to sneak into our cells.

A new study, scheduled to publish the week of Nov. 11 in Proceedings of the National Academy of Sciences, now reveals not only how one of these proteins latches onto foreign invaders, but also how some viruses--including the human immunodeficiency virus--evade capture.

Revealing the precise mechanism that makes this protein an effective antiviral in some cases is a critical first step in the path toward better methods for attacking viruses that manage to dodge it.

The protein in question, called ZAP (short for zinc-finger antiviral protein), is made by cells to restrict a virus from replicating and spreading infection. When cells detect a virus, the ZAP gene is turned on and produces more of the protein. ZAP then singles out the virus's genetic material, RNA, from the cell's native RNA and targets the viral RNA for destruction.

A team of researchers from the University of Michigan Life Sciences Institute and Rockefeller University wanted to determine how ZAP recognizes the virus's genome, and how some viruses avoid it.

A previous study from Rockefeller revealed that ZAP grabs onto only one specific sequence of neighboring nucleotides (the building blocks of DNA and RNA): a cytosine followed by a guanine, or a CG dinucleotide. Human RNAs have few CG dinucleotides, and HIV RNA has evolved to mimic this characteristic.

"The main motivation for the study was, 'How does HIV avoid this antiviral protein?'" said Jennifer Meagher, a researcher at U-M's LSI and one of the lead authors of the study. "And because we're structural biologists, we wanted to determine how ZAP 'sees' a CG dinucleotide--and how, structurally, it binds the RNA."

Using a piece of viral RNA that was genetically altered to include extra CG sequences, Meagher and her colleagues at U-M determined the structure of the ZAP protein bound to RNA, exposing the mechanisms that enable the protein to be so selective.

The researchers discovered that ZAP binds to the viral RNA at only one of the four "zinc fingers" on the protein that they considered potential binding sites. They further demonstrated that even a tiny change to that one binding site--altering just a single atom--hampered ZAP's binding ability.

Working in cells, researchers from Rockefeller found similar results when they altered ZAP's composition. They created mutant versions of ZAP that were expressed in cells infected with either normal HIV or a version of the virus enriched with CG sequences.

The mutant ZAP proteins were less able to recognize CG-enriched regions of the viral RNA in cells. They also exhibited increased binding to areas of the RNA that were not rich in CG dinucleotides, indicating that alterations impair ZAP's ability to distinguish viral RNA from human RNA.

"Natural selection appears to have shaped the ZAP protein structure in such a way to optimize the discrimination of nonself from self RNA, based on CG dinucleotide content," said Paul Bieniasz, Howard Hughes Medical Institute investigator and head of the Laboratory of Retrovirology at Rockefeller. "However, successful viruses are often one step ahead in a molecular arms race."

"This is the crucial first step in a complicated story of how the cell eventually degrades the virus's RNA," said Janet Smith, an LSI research professor and professor of biological chemistry at the U-M Medical School. "And now we know how the step is executed, and why it is not effective on HIV and other viruses that lack this CG sequence."

The research was done through the Center for HIV RNA Studies and was supported by the National Institutes of Health, Howard Hughes Medical Institute, Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor. X-ray crystallography data were collected at the U.S. Department of Energy's Advanced Photon Source at Argonne National Laboratory.
-end-
Study authors are: Jennifer Meagher, Sarah Keane, Victoria Orr, Jeanne Stuckey and Janet Smith of U-M; and Matthew Takata, Daniel Gonçalves-Carneiro, Antoine Rebendenne, Heley Ong, Margaret MacDonald and Paul Bieniasz of Rockefeller University.

The PNAS paper is titled "Structure of the zinc-finger antiviral protein in complex with RNA reveals mechanism for selective targeting of CG-rich viral sequences."

University of Michigan

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.